Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies
Silvia Tanzarella1, Ilaria Lionello, Barbara Valentinis
1MolMed, via Olgettina 58, 20132 Milan, Italy.
Abstract:
The search for alternative strategies of therapy remains a major issue for most neoplastic diseases. The expression of several tumor antigens makes human rhabdomyosarcomas, which are the most frequent form of soft tissue tumor in children, a good candidate for tumor-specific immunotherapy. To assess the feasibility of this approach, we evaluated the ability of rhabdomyosarcoma cell lines to process and present the MAGE-A tumor antigens to effectors of the immune system. To this end, we investigated recognition of MAGE-A-positive rhabdomyosarcoma cells by HLA-B*3701-restricted T cells specific for a MAGE-A-derived peptide. Low level of HLA expression impaired recognition of the tumor cells. Therefore, to obtain HLA expression avoiding the use of IFN-gamma and TNF-alpha, which could affect the proteasome activity, a rhabdomyosarcoma line was transduced by a retroviral vector encoding the HLA-B*3701 allele. Recognition of the infected cells was then observed also in the absence of IFN-gamma and TNF-alpha treatment, thus demonstrating that rhabdomyosarcoma cells were indeed able to naturally process and present the MAGE-A antigens. These results demonstrate that rhabdomyosarcoma cells expressing MAGE-A can be targets of tumor-specific effectors, suggesting the feasibility of clinical protocols of specific immunotherapy also for the treatment of rhabdomyosarcoma.
Insights
Human rhabdomyosarcoma cells expressing MAGE-A antigens can be targeted by immunotherapy. This study shows these cells can process and present MAGE-A antigens, suggesting potential for new cancer treatments.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Rhabdomyosarcoma, a common pediatric soft tissue tumor, presents a challenge for effective cancer therapies.
- Tumor antigens like MAGE-A offer potential targets for cancer-specific immunotherapy.
- Evaluating the immune system's recognition of MAGE-A-expressing rhabdomyosarcoma cells is crucial for developing new treatments.
Purpose of the Study:
- To assess the capability of rhabdomyosarcoma cell lines to process and present MAGE-A tumor antigens.
- To investigate the recognition of MAGE-A-positive rhabdomyosarcoma cells by specific T cells.
- To demonstrate the feasibility of MAGE-A-targeted immunotherapy for rhabdomyosarcoma.
Main Methods:
- Investigated recognition of MAGE-A-positive rhabdomyosarcoma cells by HLA-B*3701-restricted T cells.
- Utilized a retroviral vector to introduce the HLA-B*3701 allele into a rhabdomyosarcoma cell line, aiming to enhance HLA expression.
- Observed T cell recognition of transduced cells in the absence of IFN-gamma and TNF-alpha.
Main Results:
- Low HLA expression on tumor cells impaired T cell recognition.
- Retroviral transduction successfully increased HLA expression on rhabdomyosarcoma cells.
- Transduced cells were recognized by T cells without IFN-gamma or TNF-alpha, confirming antigen processing and presentation.
Conclusions:
- Rhabdomyosarcoma cells expressing MAGE-A antigens can be effectively processed and presented to the immune system.
- These findings support the potential of MAGE-A-targeted immunotherapy for rhabdomyosarcoma treatment.
- The study suggests the feasibility of developing clinical immunotherapy protocols for rhabdomyosarcoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy